BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/3/2023 10:22:43 AM | Browse: 327 | Download: 1263
 |
Received |
|
2023-03-20 14:48 |
|
Peer-Review Started |
|
2023-03-20 14:51 |
|
First Decision by Editorial Office Director |
|
2023-06-15 09:02 |
|
Return for Revision |
|
2023-06-15 09:02 |
|
Revised |
|
2023-06-28 16:43 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2023-07-07 02:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2023-07-07 06:31 |
|
Articles in Press |
|
2023-07-07 06:31 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-07-28 07:59 |
|
Publish the Manuscript Online |
|
2023-08-03 10:22 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinase positive non-small cell lung cancer: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Lu-Ming Wang, Peng Zhao, Xu-Qi Sun, Feng Yan and Qian Guo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Qian Guo, MD, Doctor, Doctor, Department of Medical Oncology, The First People’s Hospital of Hangzhou Lin’an District, No. 548 Yijin Street, Jincheng Street, Hangzhou 311300, Zhejiang Province, China. gqwy2007@163.com |
| Key Words |
Alectinib; Anaplastic lymphoma kinase; Non-small cell lung cancer; Neoadjuvant therapy; Case report |
| Core Tip |
Whether neoadjuvant alectinib can serve as a conversion therapy in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) remains unclear. We report the first case of ALK-positive stage IIIB NSCLC in which a pathological complete response was achieved after neoadjuvant alectinib therapy. Subsequently, left upper lobectomy with mediastinal lymphadenectomy was performed. Postoperatively, alectinib is being continued as adjuvant therapy with a recurrence-free survival of 29 mo as of date. This case report highlights the feasibility of alectinib as neoadjuvant therapy for unresectable ALK-positive locally advanced NSCLC. |
| Publish Date |
2023-08-03 10:22 |
| Citation |
Wang LM, Zhao P, Sun XQ, Yan F, Guo Q. Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinase positive non-small cell lung cancer: A case report. World J Clin Cases 2023; 5322-5328 |
| URL |
https://www.wjgnet.com/2307-8960/full/v11/i22/5322.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v11.i22.5322 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
